alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014351EN.01002802.xml

| 6.10.2014 | EN | Official Journal of the European Union | C 351/28 |
| --- | --- | --- | --- |

6.10.2014

EN

Official Journal of the European Union

C 351/28

---

Action brought on 18 August 2014 — Wm. Wrigley Jr. v OHIM (Device of a sphere)

(Case T-625/14)

2014/C 351/37

Language of the case: English

Parties

Parties

Applicant: Wm. Wrigley Jr. Company (Wilmington, United States) (represented by: M. Kinkeldey, S. Brandstätter and C. Schmitt, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Fifth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 17 June 2014 given in Case R 168/2014-5. |
| --- | --- |

—

Annul the decision of the Fifth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 17 June 2014 given in Case R 168/2014-5.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: The figurative mark representing a device of a sphere for goods in classes 3, 21 and 30 — Community trade mark application No 1 1 7 37  541

Community trade mark concerned:

Decision of the Examiner: Partially rejected the CTM application

Decision of the Examiner:

Decision of the Board of Appeal: Dismissed the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 7(1)(b) CTMR.

Pleas in law:

---
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.3900 Standup wheelchair. ( a ) *Identification.* A standup wheelchair is a device with wheels that is intended for medical purposes to provide mobility to persons restricted to a sitting position. The device incorporates an external manually controlled mechanical system that is intended to raise a paraplegic to an upright position by means of an elevating seat.
( b ) *Classification.* Class II (performance standards).
Exhibit 31

Certifications

I, Richard Simpson, certify that:

1.I have reviewed this report on Form 10-K and all reports on Form 10-D required to be filed in respect of the period covered by this report on Form 10-K of Citigroup Commercial Mortgage Trust 2015-P1 (the “Exchange Act periodic reports”);

2.Based on my knowledge, the Exchange Act periodic reports, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, all of the distribution, servicing and other information required to be provided under Form 10-D for the period covered by this report is included in the Exchange Act periodic reports;

4.Based on my knowledge and the servicer compliance statement(s) required in this report under Item 1123 of Regulation AB, and except as disclosed in the Exchange Act periodic reports, the servicers have fulfilled their obligations under the servicing agreements in all material respects; and

5.All of the reports on assessment of compliance with servicing criteria for asset-backed securities and their related attestation reports on assessment of compliance with servicing criteria for asset-backed securities required to be included in this report in accordance with Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to this report, except as otherwise disclosed in this report.  Any material instances of noncompliance described in such reports have been disclosed in this report on Form 10-K.

In giving the certifications above, I have reasonably relied on information provided to me by the following unaffiliated parties: Wells Fargo Bank, National Association; LNR Partners, LLC; Park Bridge Lender Services LLC; Computershare Trust Company, National Association; CoreLogic Solutions, LLC; Berkadia Commercial Mortgage LLC; Principal Real Estate Investors, LLC; Berkeley Point Capital LLC; Deutsche Bank Trust Company Americas; and Wilmington Trust, National Association.

Date:March 31, 2022

|  | /s/ Richard Simpson ___________________Richard SimpsonPresident, Citigroup Commercial Mortgage Securities Inc.(senior officer in charge of securitization of the depositor) |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

CGCMT 2015-P1 Certifications
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.2560 Microbial growth monitor. ( a ) *Identification.* A microbial growth monitor is a device intended for medical purposes that measures the concentration of bacteria suspended in a liquid medium by measuring changes in light scattering properties, optical density, electrical impedance, or by making direct bacterial counts. The device aids in the diagnosis of disease caused by pathogenic microorganisms.
( b ) *Classification.* Class I. With the exception of automated blood culturing system devices that are used in testing for bacteria, fungi, and other microorganisms in blood and other normally sterile body fluids, this device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter.
[47 FR 50823, Nov. 9, 1982, as amended at 60 FR 38482, July 27, 1995]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4494 Absorbable poly(hydroxybutyrate) surgical suture produced by recombinant DNA technology. ( a ) *Identification.* An absorbable poly(hydroxybutyrate) surgical suture is an absorbable surgical suture made of material isolated from prokaryotic cells produced by recombinant deoxyribonucleic acid (DNA) technology. The device is intended for use in general soft tissue approximation and ligation.
( b ) *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Absorbable Poly(hydroxybutyrate) Surgical Suture Produced by Recombinant DNA Technology.” For the availability of this guidance document see § 878.1(e).
[72 FR 43146, Aug. 3, 2007]
<PAGE>
                                                                    EXHIBIT 10.2


                                                        August 4, 2003


Biopure Corporation
11 Hurley Street
Cambridge, MA 02141

         Re: Lock-up of Securities

Gentlemen:

     I am a director of Biopure Corporation ("Biopure"). I hold 189,112 shares
of Class A Common Stock of Biopure ("Common Stock") together with associated
Common Stock warrants to purchase 37,822 additional shares (collectively, the
"Securities") which were issued in an offering on March 25, 2003 (the
"Offering"). You intend to seek stockholder approval for sales to insiders in
the Offering at the 2004 annual meeting of stockholders. At your request, in the
interim, I agree that the Securities shall not be sold, transferred, assigned,
pledged or hypothecated, nor will I vote any of the Common Stock included in the
Securities. In addition, if the Company pays a dividend on its Common Stock,
dividends on the Securities will be withheld.


                                                  Very truly yours,



                                                  Thomas A. Moore
Exhibit 23.1

INDEPENDENT AUDITORS' CONSENT

We consent to the  incorporation  by reference in  Registration  Statement  Nos.
33-46559,  33-46561, 33-46563, 33-46573, 33-68806, 33-68808, 33-62631, 33-62633,
333-40974, and 333-49894 of Elcotel, Inc. on Forms S-8, of our report dated July
3, 2001 (which report expresses an unqualified opinion and includes  explanatory
paragraphs  dealing with  uncertainties  relating to i) the Company's filing for
reorganization  under  Chapter 11 of the Federal  Bankruptcy  Code,  and ii) the
Company's  ability to continue  as a going  concern),  appearing  in this Annual
Report on Form 10-K of Elcotel, Inc. for the year ended March 31, 2001.

Deloitte & Touche LLP

Certified Public Accountants

Tampa, Florida
July 10, 2001
# C_2014151EN.01003302.xml

| 19.5.2014 | EN | Official Journal of the European Union | C 151/33 |
| --- | --- | --- | --- |

19.5.2014

EN

Official Journal of the European Union

C 151/33

---

Action brought on 24 March 2014 — Swedish Match North Europe v OHIM — Skruf Snus (Oral snuff packages)

(Case T-196/14)

2014/C 151/43

Language in which the application was lodged: English

Parties

Parties

Applicant: Swedish Match North Europe AB (Stockholm, Sweden) (represented by: H. Wistam and L. Holm, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Skruf Snus AB (Stockholm, Sweden)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Third Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 3 December 2013 given in Case R 1803/2012-3; |
| --- | --- |

—

Annul the decision of the Third Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 3 December 2013 given in Case R 1803/2012-3;

| — | Order the defendant to pay the costs of proceedings. |
| --- | --- |

—

Order the defendant to pay the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Registered Community design in respect of which a declaration of invalidity has been sought: A design for the product ‘oral snuff packages’ — registered under No 1265805-0010

Registered Community design in respect of which a declaration of invalidity has been sought:

Proprietor of the Community design: The other party to the proceeding

Proprietor of the Community design:

Applicant for the declaration of invalidity of the Community design: The applicant

Applicant for the declaration of invalidity of the Community design:

Grounds for the application for a declaration of invalidity: It was alleged that the design lacked an individual character

Grounds for the application for a declaration of invalidity:

Decision of the Cancellation Division: Upheld the application for a declaration of invalidity of the contested RCD

Decision of the Cancellation Division:

Decision of the Board of Appeal: Annulled the contested decision and dismissed the application for a declaration of invalidity

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 6 CDR.

Pleas in law:

---
Exhibit 32.1

STATEMENT OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the Form 10-Q of Hilb Rogal & Hobbs Company for the quarter ended June 30, 2007, I, Martin L. Vaughan, III, Chairman and
Chief Executive Officer of Hilb Rogal & Hobbs Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(a) such Form 10-Q for the quarter ended June 30, 2007 fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934,
as amended; and

(b) the information contained in such Form 10-Q for the quarter ended June 30, 2007 fairly presents, in all material
respects, the consolidated financial condition and results of operations of Hilb Rogal & Hobbs Company and its subsidiaries as of and for the periods presented in such Form 10-Q.



| |  |     |  |                                      |  |  |  |       |  |               
| |  | --- |  | ------------------------------------ |  |  |  | ----- |  | --------------
| |  | By: |  | /s/ Martin L. Vaughan, III           |  |  |  | Date: |  | August 6, 2007
| |  |     |  | Martin L. Vaughan, III               |  |  |  |       |  |               
| |  |     |  | Chairman and Chief Executive Officer |  |  |  |       |  |
Editorial Note on Part 860
Editorial Note: Nomenclature changes to part 860 appear at 73 FR 35341, June 23, 2008, and at 86 FR 54846, Oct. 5, 2021.

§ 860.200 Purpose and applicability. ( a ) The purpose of this part is to establish an efficient, transparent, and thorough process to facilitate De Novo classification into class I or class II for devices for which there is no legally marketed device on which to base a review of substantial equivalence and which meet the definition of class I or class II as described in section 513(a)(1) of the Federal Food, Drug, and Cosmetic Act and § 860.3.
( b ) De Novo requests can be submitted for a single device type: ( 1 ) After receiving a not substantially equivalent determination in response to a premarket notification (510(k)), or
( 2 ) If a person determines there is no legally marketed device upon which to base a determination of substantial equivalence.
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.4070 Powered corneal burr. ( a ) *Identification.* A powered corneal burr is an AC-powered or battery-powered device that is a motor and drilling tool intended to remove rust rings from the cornea of the eye.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
[55 FR 48443, Nov. 20, 1990; 55 FR 51799, Dec. 17, 1990, as amended at 65 FR 2321, Jan. 14, 2000; 84 FR 71817, Dec. 30, 2019]
§ 876.1450 Esophageal tissue characterization system. ( a ) *Identification.* An esophageal tissue characterization system is a device intended for obtaining measurements of electrical properties within esophageal tissue.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) All patient contacting components of the device must be demonstrated to be biocompatible.
( 2 ) Performance testing must demonstrate the device can accurately measure the designated electrical characteristics.
( 3 ) Mechanical safety testing must demonstrate that the device will withstand forces encountered during use.
( 4 ) Software verification, validation, and hazard analysis must be performed.
( 5 ) Electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety of the device must be performed.
( 6 ) Performance data must validate the reprocessing instructions for any reusable components of the device.
( 7 ) Labeling must include: ( i ) Specific instructions regarding the proper placement and use of the device;
( ii ) Instructions for reprocessing of any reusable components; and
( iii ) An expiration date for single use components.
[86 FR 68399, Dec. 2, 2021]
p.1 

OAR Box 1819 

Prepped by Ollie Stewart 

Document Number: 

11) IV-D-15 

Docket Number: 

A-87-11 

Printed 11/10/2008 8:56:54 AM Sheet 11 of 348 
P.2 

w=o£ 

Environmental and Safety

 Th e

 American Road 

Engineering Staff Dearborn, Michigan 48121 

Ford Motor Company 

October 5, 1987 

Mr. Glen Passavant 

U.S. Environmental Protection Agency 

2565 Plymouth Road 

Ann Arbor, Michigan 48105 

Dear Mr. Passavant: 

Subject: EPA Liquid Seal Feasibility Study 

At our September 16, 1987 meeting EPA graciously offered to show Ford n 

representatives the current status of EPA's liquid seal refueling control 

demonstration project. Several of our engineers involved in refueling control 

systems are anxious to meet with EPA to get a better understanding of your 

liquid seal system. As I have been unable to reach you by phone, I am 

requesting a meeting, preferably before the upcoming hearing. 

Please give me a call on (313) 845-8247 to arrange a date and time. 

I look forward to meeting with you and hope we can continue to work together on 

refueling control options. 

'/•-•/' / ' 

• W. M'. 'Kreucher 

WMK.83
ANDES 7 Inc.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 

AS ADOPTED PURSUANT TO SECTION 906 OF 

THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report ofANDES 7 Inc. (the Registrant) on Form 10-K/A for the period ended December 31, 2017 as filed with the Securities and Exchange Commissionon the date hereof (the Report), I, Andrew Khor Poh Kiang, Principal  Executive  Officer of the Company, certify, pursuant to 18 U.S.C.  ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

  

(1)  The Report fully complies with the requirements ofsection 13(a) or 15(d) of the Securities Exchange Act of 1934; and

  

(2)  The information contained inthe Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

A signed original of this written statement requiredby Section 906 has been provided to Andrew Khor Poh Kiang and will be retained by ANDES 7 Inc. and furnishedto the Securities and Exchange Commission or its staff upon request.

  

 

Dated: April 16, 2018

 

 

By: /s/ Andrew Khor Poh Kiang

Andrew Khor Poh Kiang

President, Chief Executive Officer, Chairman

(Principal Executive Officer)

 

 

ANDES 7 Inc.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 

AS ADOPTED PURSUANT TO SECTION 906 OF 

THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report ofANDES 7 Inc. (the Registrant) on Form 10-K/A for the period ended December 31, 2017 as filed with the Securities and Exchange Commissionon the date hereof (the Report), I, Lee Kok Keing, Principal Financial Officer of the Company, certify,  pursuant to18 U.S.C.  ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

  

(1)  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

  

(2)  The information contained inthe Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

A signed original of this written statement requiredby Section 906 has been provided to Lee Kok Keing, and will be retained by ANDES 7 Inc. and furnished to theSecurities and Exchange Commission or its staff upon request.

  

 

Dated: April 16, 2018

 

 

By: /s/ Lee Kok Keing

Lee Kok Keing

Chief Financial Officer 

(Principal Financial Officer)
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4525 Microsurgical instrument. ( a ) *Identification.* A microsurgical instrument is a nonpowered surgical instrument used in neurological microsurgery procedures.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9.
[44 FR 51730, Sept. 4, 1979, as amended at 59 FR 63012, Dec. 7, 1994; 66 FR 38808, July 25, 2001]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5790 Tracheal tube stylet. ( a ) *Identification.* A tracheal tube stylet is a device used temporarily to make rigid a flexible tracheal tube to aid its insertion into a patient.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
§ 74.303 FD&C Red No. 3. ( a ) *Identity.* ( 1 ) The color additive FD&C Red No. 3 is principally the monohydrate of 9 (*o-* carboxyphenyl)-6-hydroxy - 2,4,5,7-tetraiodo-3H-xanthen-3-one, disodium salt, with smaller amounts of lower imdinated fluoresceins.
( 2 ) Color additive mixtures for food use made with FD&C Red No. 3 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring foods.
( b ) *Specifications.* FD&C Red No. 3 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Volatile matter (at 135 °C.) and chlorides and sulfates (calculated as the sodium salts), total not more than 13 percent. Water-insoluble matter, not more than 0.2 percent. Unhalogenated intermediates, total not more than 0.1 percent. Sodium iodide, not more than 0.4 percent. Triiodoresorcinol, not more than 0.2 percent. 2(2′,4′-Dihydroxy-3′, 5′-diiodobenzoyl) benzoic acid, not more than 0.2 percent. Monoiodofluoresceins not more than 1.0 percent. Other lower iodinated fluoresceins, not more than 9.0 percent. Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Total color, not less than 87.0 percent.
( c ) *Uses and restrictions.* FD&C Red No. 3 may be safely used for coloring foods generally (including dietary supplements) in amounts consistent with good manufacturing practice except that it may not be used to color foods for which standards of identity have been promulgated under section 401 of the act unless added color is authorized by such standards.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of FD&C Red No. 3 shall be certified in accordance with regulations in part 80 of this chapter.
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1910 Spectacle dissociation test system. ( a ) *Identification.* A spectacle dissociation test system is an AC-powered or battery-powered device, such as a Lancaster test system, that consists of a light source and various filters, usually red or green filters, intended to subjectively measure imbalance of ocular muscles.
( b ) *Classification.* Class I (general controls). The AC-powered device and the battery-powered device are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The battery-powered device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[55 FR 48442, Nov. 20, 1990; 55 FR 51799, Dec. 17, 1990, as amended at 59 FR 63013, Dec. 7, 1994; 66 FR 38813, July 25, 2001]
[Federal Register Volume 75, Number 47 (Thursday, March 11, 2010)]
[Notices]
[Page 11537]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-5037]


=======================================================================
-----------------------------------------------------------------------

FEDERAL ELECTION COMMISSION


Sunshine Act Notice

DATE and TIME: Thursday, March 11, 2010, at 10 a.m.

PLACE: 999 E Street, NW., Washington, DC (Ninth floor).

STATUS: This meeting will be open to the public.

ITEMS TO BE DISCUSSED: Correction and Approval of Minutes.
    Draft Advisory Opinion 2010-02: West Virginia Republican Party, 
Inc. by its chairman, Douglas E. McKinney, M.D.
    EMILY's List: Final Rules and Explanation & Justification.
    Management and Administrative Matters.
    Individuals who plan to attend and require special assistance, such 
as sign language interpretation or other reasonable accommodation, 
should contact Darlene Harris, Acting Commission Secretary, at (202) 
694-1040, at least 72 hours prior to the hearing date.

PERSON TO CONTACT FOR INFORMATION: Judith Ingram, Press Officer, 
Telephone: (202) 694-1220.

Darlene Harris,
Acting Secretary of the Commission.
[FR Doc. 2010-5037 Filed 3-10-10; 8:45 am]
BILLING CODE 6715-01-M